N/A N=200 An Electronic Health Record-based Approach to Increase PrEP Knowledge and Uptake: the EMC2 PrEP Strategy
HIV Infections · Electronic Health Record · Primary Health Care
Primary: PrEP Uptake (Use) — 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=28 Sepsis-Associated Purpura Fulminans International Registry - Europe
Sepsis
Primary: Mortality — 11 Participants
Phase 3 N=400 Fontan Udenafil Exercise Longitudinal Assessment Trial
Single Ventricle Heart Disease
Primary: Change in Maximal VO2 From Baseline to Week 26 Using Last Observation Carried Forward (LOCF) — -0.23; -0.89 mL/kg/min — p=0.092
Phase 2 N=46 A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
Advanced Solid Tumors
Primary: Part A: Number of Participants With Dose-limiting Toxicities (DLTs) Based on Common Terminology Criteria for Adverse Events (CTCAE) — 0; 0; 0; 2 Participants
N/A N=30 Investigating Central Neurophysiologic Correlates of Non-Motor Symptoms of Parkinson's Disease
Parkinson Disease · Autonomic Dysfunction · Depression
Primary: Change in Frontal Midline Theta EEG Power After Brain Stimulation — 1.03; 0.44; 1.01 microvolts^2/Hz — p=0.08
Phase 2 N=36 A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Change From Baseline in the Peak Esophageal Intraepithelial Eosinophil Count at Week 4 (Mean) — -9.2; -31.6; -7.8 eosinophil count per high power field
N/A N=23 Standardized Patient-Centered Medication Review in Home Hospice
Hospices · Poly Pharmacy · Deprescriptions
Primary: Intervention Training Completion by Hospice Staff — 17; 0 Participants
N/A N=7 Senior PharmAssist: Co-Design and Evaluation of a Toolkit to Promote Scalable Implementation
Medication Therapy Management · Implementation Science
Primary: Number of Older Adults Seeking Service Who Received All 4 Components of Senior PharmAssist Intervention — 0 Participants
N/A N=228 Treatment of Pregnant Women With OUD
Opioid-use Disorder
Primary: Treatment Engagement — 78; 64; 109; 92 Participants — p=0.5340
Phase 2 N=195 A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease
Uncontrolled Hypertension · Chronic Kidney Diseases
Primary: Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) of Pooled CIN-107 and Placebo — -15.22; -7.15 Millimeters of mercury (mmHg) — p=0.003
Phase 1 N=12 A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041
Type I Diabetes
Primary: Adverse Events — 230; 217; 215; 169 adverse events
N/A N=44 Developing a Team-Delivered Intervention for Smoking and Hazardous Drinking for Primary Care Veterans With Cardiovascular Diseases
Cigarette Use · Alcohol Use Above Recommended Limits · Cardiovascular Risk Factors (e.g., Hypertension)
Primary: Readiness to Change Drinking OR Smoking — 2; 4; 4; 8 Participants
Phase 3 N=91 Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions
Anal Intraepithelial Neoplasia · High-grade Squamous Intraepithelial Lesion · HIV Infection
Primary: Percentage of Participants Achieving Complete Response in 5-FU Arm and Observation Arm Using ITT Population — 5; 9 Participants — p=0.1877
Phase 2 N=7 Targeting IL-17A for Treatment-Resistant Depression
Major Depressive Disorder
Primary: Number of Participants Who Dropped-out — 0 Participants
N/A N=22 Evaluation of a Novel Sutureless Drain Securement Device
Skin Injury
Primary: Time it Takes to Secure and Dress Each Drain in Totality — 67; 79; 114; 94 Seconds